U.S. Markets close in 14 mins

TransEnterix Senhance Surgical Robotic System Wins FDA Nod

Zacks Equity Research

TransEnterix, Inc. TRXC announced the receipt of FDA 510(k) clearance for the Senhance Surgical Robotic System. Senhance is a multiport surgical robotic system which helps perform minimally invasive surgery.It is the first FDA-approved entrant in the field of abdominal surgical robotics since 2000. This development is going to fortify TransEnterix’s medical device robotics segment’s business.

According to the company, the Senhance Surgical Robotic System helps surgeons direct small surgical instruments and a camera with robotic precision. Also, it offers the security of haptic feedback and eye-sensing camera control for the first time in a robotic surgery platform while minimizing procedural costs.

The Senhance enables hospitals and surgeons to leverage on technology investments within the operating room ecosystem. This system makes robotic surgery cost-effective on a per-procedure basis as it uses fully reusable instruments.

 

Recently, TransEnterix sold a Senhance Robotic Surgery System to a Japanese customer. It was sold to the Saitama Medical University International Medical Center located in the Saitama Prefecture in the Greater Tokyo region. Moreover, the system got installed in the Imperial College of London, U.K. Notably, Senhance is CE Marked for use in general, gynecology, urology and thoracic surgery.

According to a report by Markets and Markets, the minimally invasive surgical instruments market is forecasted to reach a value of $21.47 billion by 2021, at a CAGR of 9.1%. Considering the substantial potential of the market, we believe the latest development is a strategic one.

TransEnterix’s shares have outperformed the industry in the past three months. The stock has skyrocketed 87.8% compared with the industry's 1.2% gain in the same period. The current level is better than the S&P 500's return of 3.5%.

Estimate Revision Trend

The estimate revision trend has been favorable for the company. For the current year, one estimate moved north compared with no movement in the opposite direction over the last month. As a result, the Zacks Consensus Estimate for the current year has narrowed to a loss of 38 cents per share from a loss of 51 cents.

Zacks Rank & Key Picks

TransEnterix has a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott ABT, IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 34.6% over the last year.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 43.4% last year.

Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 27.6% last year.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>